More coverage but more cost: Are we better off now than 20 years ago?
Uninsurance rates have fallen over the past 20 years, but has health care become more affordable? More
Uninsurance rates have fallen over the past 20 years, but has health care become more affordable? More
Affordability is one of the most important considerations for hospital patients. So why isn't billing taken into account in hospital evaluations? More
"Screening saves lives" is a popular sentiment. But what about the potential downsides of cancer screening? More
Many physicians see drug samples as a benefit, because they can give pills to patients who may not be able to afford the medication otherwise. But are these "free" samples really free? More
An example of an abstract. Enter an abstract here. More
Report finds health care spending grew 146 percent in the past decade—wasting billions in the process on overpriced services and unnecessary care—while spending on community conditions grew by just 39 percent. More
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent varius odio orci, ac faucibus elit varius eu. Aliquam consectetur pulvinar justo posuere laoreet. Aenean mi dui, dapibus et imperdiet eget, feugiat at arcu. Sed et ex in tellus molestie sodales tincidunt id massa. Donec rutrum consectetur dapibus. Curabitur fringilla, magna eu tristique pellentesque, metus turpis […] More
In a new report, the Lown Institute calls for a national action plan to address overprescribing. More
Each year, JAMA Internal Medicine publishes an update on overuse, featuring the top ten most influential articles on overuse from the previous year. Here are some highlights from this year's update! More
If you thought the only takeaway from ORBITA was "stents don't work," you're missing the point, says Dr. Vikas Saini in Health Affairs. More
If stents for stable angina don't work, what else doesn't work? As it turns out, arthroscopic surgery for shoulder pain... More
The ORBITA debate continues as the study authors respond to critical letters in The Lancet. More
Cancer advocacy groups are cheering the new screening guidelines for colorectal cancer, but few reports have examined both the costs and benefits of lowering the age of screening. More
Catheter ablation for atrial fibrillation has been used for 20 years, and grown into a $4.5 billion industry. But is the procedure actually effective? More
Are we oversimplifying the discussion when it comes to overuse? In a NEJM editorial, Lisa Rosenbaum argues that "less is more" can be a slippery slope. Here's what we thought about her controversial piece. More
Professor Doug McKell explains why ORBITA might not be enough to reduce unnecessary stents. More
Why was Gardasil originally marketed as a cervical cancer vaccine? Professor Samantha Gottlieb explains. More
Cardiologist David Brown addresses some of the criticisms of the controversial ORBITA trial. More
A study in The Lancet this week has rocked the world of cardiology by showing that stents are no better than a placebo in relieving chest pain. More
Why is clinical research such a mess? And how can we clean it up? More